



*Delivering highly effective infection control products*

## MARKET OPPORTUNITY

The outbreak of SARS and growing concerns with other infectious diseases such as the Avian Flu has highlighted the need for more effective infection control. The worldwide market for infection control products is projected to exceed USD \$200 billion. Hard surface disinfectants alone command ~USD \$10 billion in annual sales.


ALDA has successfully established a family of infection control products in the Canadian market place. ALDA's T<sup>3</sup>6<sup>®</sup> technology is the basis for other infection control products already in late-stage development.

ALDA's competitive advantage resides in the ability of its proprietary T<sup>3</sup>6<sup>®</sup> formulation to completely and safely destroy infectious organisms using non-toxic, non-corrosive and biodegradable ingredients.

The technology is supported by a full range of efficacy and toxicology studies conducted in the USA and Canada. ALDA management and in-house sales personnel work as a team in order to assist distributors, increase online sales and ensure product recognition.

## APH:TSX-V CORPORATE HIGHLIGHTS

- Develops and markets a family of powerful and safe infection control products based on its proprietary T<sup>3</sup>6<sup>®</sup> technology (patents pending).
- ALDA's lead product, T<sup>3</sup>6<sup>®</sup> Disinfectant is a hospital grade, wide-spectrum, non-toxic, non-corrosive surface disinfectant.
- T<sup>3</sup>6<sup>®</sup> "Ready-To-Use" Disinfectant Cleaner for retail and home use where a more economical and lower level of disinfection is required .
- T<sup>3</sup>6<sup>®</sup> "Ready-To-Use" Disinfectant Cleaner Concentrate for industrial and institutional use.
- T<sup>3</sup>6<sup>®</sup> Disinfectant is used by the BC Ambulance Service, Product Distribution Centre of BC, Vancouver Fire Department, RCMP, hospitals, HIV Reference Laboratories, medical & dental clinics.
- Health Canada GMP-certified facility is ready to meet anticipated sales increase.
- Experienced, professional management.
- Debt-free company with good corporate governance protocol.



SARS Virus



# T<sup>3</sup>6<sup>®</sup> Disinfectant

## ALDA'S FIRST INFECTION CONTROL PRODUCT

*T<sup>3</sup>6<sup>®</sup> Disinfectant is used by the B.C Ambulance Service, the largest ambulance service in the world and by the National Laboratory for HIV Reference Services.*

All testing of T<sup>3</sup>6<sup>®</sup> Disinfectant has been carried out by highly prestigious, independent institutions including:

- BC Children's Hospital
- The John Ruedy Immunodeficiency Clinic at St. Paul's Hospital
- The University of British Columbia
- BCResearch Inc.
- Product Safety Labs in New Jersey, USA
- ATS Laboratories in Minnesota, USA
- ViroMed Biosafety Laboratories in Minnesota, USA

**T<sup>3</sup>6<sup>®</sup> Disinfectant** is a hospital-grade, wide-spectrum, surface spray disinfectant that has been tested on over 50 varieties of bacteria, viruses and fungi.

**T<sup>3</sup>6<sup>®</sup> Disinfectant** kills all of these infectious organisms within 3 minutes, including HIV, Polio, Legionella and the Norwalk-like virus. It kills tuberculosis (TB) in 5 minutes, is 100 times more effective than the specified requirement for hospital use and exceeds the kill rate of other disinfectants on the market.

**T<sup>3</sup>6<sup>®</sup> Disinfectant** has been granted a Health Canada DIN number and has been approved by the Therapeutics Product Directorate (TPD) for health safety applications and the Canadian Food Inspection Agency (CFIA) for use in food processing facilities, restaurants and other food handling establishments.

**T<sup>3</sup>6<sup>®</sup> Disinfectant** is non-corrosive, non-caustic, non-hazardous, biodegradable, highly effective and competitively priced.

The emergence of SARS, Norwalk virus, Avian flu, drug-resistant "super bugs", new strains of TB and other bacterial, viral and fungal pathogens has increased the market demand for highly effective and non-toxic disinfectants.



*Mycobacterium tuberculosis*

## T<sup>3</sup>6<sup>®</sup> Future Products

ALDA has recognized the need for and is developing a product pipeline based on its T<sup>3</sup>6<sup>®</sup> infection control technology for:


- Commercial applications
- Personal use
- Household use
- Veterinary use
- Therapeutic treatments
- Surgical and diagnostic applications

Further patents are in progress and developmental work has been completed on most of these products. Clinical trials for therapeutic treatments will be undertaken as quickly as possible. Some products may require additional specific testing for regulatory purposes.



## Infectious Disease - A Growing Problem

The World Health Organization (WHO) has stated that *NEW* diseases such as SARS and Avian Flu are emerging at a rate of at least one every year. This exacerbates the impact of familiar killer diseases such as HIV/AIDS, (over 20 million thus far) and *Streptococcus pneumoniae* (1.8 million annually).



Influenza virus

- The Infectious Diseases Society of America (IDSA): "Infectious diseases don't respect borders and can move easily from one part of the world to another."
- Centers for Disease Control & Prevention (CDC): "An influenza pandemic could result in over 200,000 deaths in the U.S." 2 million people acquire bacterial infections in U.S. hospitals annually. 70 % of these infections are drug resistant.
- WHO: "The world is in danger of an influenza pandemic", and warns, "The health impact of a more virulent bird flu will be much greater than SARS".
- The Institute of Medicine (IOM) estimates the total annual cost of antimicrobial resistance to U.S. society is nearly \$5 billion.

Naturally occurring infectious diseases are the 2nd leading cause of death worldwide and the 3rd leading cause of death in the U.S. Programs are being threatened by fewer treatment initiatives, less funding and research cuts.

Effective infection control practices can help to minimize this human devastation as many of these diseases are spread through contact with contaminated surfaces.

Leading Causes of Death Due to Infectious Diseases	2002
Lower respiratory infections	3.9 million
HIV/AIDS	2.8 million
Diarrheal diseases	1.8 million
Tuberculosis	1.6 million
Malaria	1.2 million
Measles	0.6 million

Source:  
WHO  
World Health Report, 2004

## T<sup>3</sup>6<sup>®</sup> INFECTION CONTROL - AN EMERGING SOLUTION

**T<sup>3</sup>6<sup>®</sup> Disinfectant** is a superior, *non-toxic*, broad spectrum disinfectant for low, medium and high risk situations and for the disinfection of semi-critical instrumentation.

- Environmentally friendly and bio-degradable.
- Non-corrosive. No caustic chemicals.
- Bactericidal, Virucidal, Fungicidal, Tuberculocidal.
- Safe, ready-to-use hospital-grade disinfectant, sanitizer and deodorizer.
- Effective against HIV, Legionella, the surrogate of Norwalk virus and Polio
- Broad surface compatibility leaves no residue that can *alter* or *adhere* to treated surfaces.
- Pleasant odor and excellent detergency properties.
- Manufactured in a Health Canada GMP-certified facility with production capability of up to 6 million units per year.
- Competitively priced and available in 480 ml , 4 liter and 20 liter quantities.



## DIRECTORS & MANAGEMENT

### Terrance G. Owen – PhD, MBA

*CEO, President & Director*

Dr. Owen has degrees in both Science and Business. He was President of Helix Biotech, a company that provides DNA identity testing for paternity, immigration and forensics. He took the company public on the VSE before listing on the TSE. Terry co-founded the Capital Pool Company, Duft Biotech, which later acquired the assets of ALDA.

### Peter Chen

*CFO, Secretary & Director*

Mr. Chen was the CFO of Prospect Point Exploration and Management Services Ltd. He also served as President and CFO of Canadian Mineral Exploration Managing Consultants Inc., and provided services to publicly listed companies with projects in South East Asia and Africa. He is a Director of the Douglas College Foundation and co-founder of Duft Biotech.

### Allan H. Shapiro – BSc, DDS, FAGD

*Manager of Business Development, Founder & Inventor*

Dr. Shapiro founded ALDA in 1996 and developed ALDA's infection control technology and products. He was awarded a Fellowship in the U.S. Academy of General Dentistry.

Dr. Shapiro practiced for over twenty years, is a member of the American Industrial Hygiene Ass'n. and has co-authored several scientific research papers on infection control.

### Ronald Zokol – DMD

*Director*

Dr. Zokol has been practicing dentistry for 31 years. He is the director of the Pacific Institute for Implant Dentistry and a Diplomat of the American Board of Oral Implantology. He lectures internationally in implant surgery and prosthodontics. He was elected President of the Vancouver and District Dental Society in 1986 and teaches advanced reconstructive dentistry.

### Linda Allison – BSc, MSc, DIC, PhD

*Director*

Dr. Allison is the President of Snowdon & Associates Management Consultants, where she provides professional services to medical technology and biotech companies. In addition, she has over six years experience in corporate finance and has provided senior management services to biomedical companies. Since 1999, Dr. Allison has advised ALDA on the development of its strategic plan.

### Eugene Hodgson

*Director*

Mr. Hodgson is the president of Seeds Capital Inc., and E.A. Hodgson and Associates Inc. He currently serves as both CFO and Director of Sea Breeze Power Inc. and is a Director and co-founder of the "Families for School Seismic Safety" in BC.

Mr. Hodgson is a former Director of the Vancouver Board of Trade and Treasurer of the Liberal Party of Canada (for BC).

### William McCoy, PhD

*Director*

Dr. McCoy is Chief Technology Officer for Phigenics, LLC, a life sciences technology company based in Chicago, Illinois. He serves on the World Health Organization (WHO) committee. Dr. McCoy received the Intellectual Property Law Association "2001 Inventor of the Year" award and has been commissioned to write a book for The International Water Association.

## SCIENTIFIC & INDUSTRY ADVISORS

### Brian Conway, MD, FRCPC

*Scientific Advisor*

Dr. Conway is a Professor in Pharmacology & Therapeutics at UBC and is a Coordinator of the Downtown Infectious Diseases Clinic. He evaluates anti-HIV drugs and researches acute and early HIV infections and treatment. Dr. Conway conducted the original efficacy testing of T<sup>3</sup>6<sup>®</sup> Disinfectant on HIV.

### Michael Wilby, BSc, DDS, Cert. Periodontology

*Scientific Advisor*

Dr. Wilby is co-founder of ALDA and co-developer of the T<sup>3</sup>6<sup>®</sup> technology. He is a Diplomat of the Int'l Congress of Oral Implantologists and is on the teaching staff in Graduate Periodontology at UBC and lectures locally and internationally. Dr. Wilby has specialty practices in periodontics and dental implants in Richmond, BC and in Whitehorse, Yukon.

### Bruce Schmidt – BSc

*Biotechnology Business Advisor*

Mr. Schmidt is an independent management consultant servicing the life sciences sector. He is currently involved with Genome British Columbia, Biophage Pharma, B.C. Bioproducts Ass'n and the B.C. Nanotechnology Initiative. Mr. Schmidt was a Founding Director of Genome British Columbia, past Chairman of B.C. Biotech, co-founder of Duft Biotech Capital and former Director of ALDA Pharmaceuticals Corp.

## APH:TSX-V Share Structure

(As of December 31, 2005)

Authorized:	100,000,000
Issued & Outstanding:	19,700,404
Warrants:	7,136,500
Options:	1,252,500
Fully-Diluted	28,089,404

### ALDA Pharmaceuticals Corp.

635 Columbia Street

New Westminster, BC V3M 1A7

Phone: 604-521-8300 Fax: 604-521-8322

Toll Free: 1-866-521-ALDA (2532)

## For Additional Information Visit:

[www.aldacorp.com](http://www.aldacorp.com)

**Sales & Product Info:** Aaron Genereaux  
aaron@aldacorp.com (604) 521-8300

**Investor contact:** Scott Young  
scott\_young@aldacorp.com (778) 371-9100